1346576-20-2

Upstream product

• 42762-51-6 (E)-5-phenyl-3-penten-2-one 
• 107-91-5 cyanoacetic acid amide 
• 101-97-3 Ethyl 2-phenylethanoate 
• 3318-61-4 1-phenyl-2,4-pentanedione 

Downstream Products

• 1346576-21-3 3-(aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone 
• 1346576-22-4 3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone 
• 1346576-23-5 1,1-dimethylethyl {[4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate 

Relevant academic research and scientific papers

IMIDAZOPYRIDINE EZH2 INHIBITORS

The present invention relates to imidazopyridines of general formula (I), to a method for their preparation, to intermediates for their preparation, to pharmaceutical compositions comprising at least one of those compounds, and to the use thereof.

METHOD OF TREATMENT

The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

AZAINDAZOLES

Herein are disclosed azaindazoles of formula (I), (I), where the various groups are defined herein, and which are useful for treating cancer.